Hall K, Otten N, Johnston B, Irvine-Meek J, Leroux M, Seshia S
J Clin Pharmacol. 1985 May-Jun;25(4):261-8. doi: 10.1002/j.1552-4604.1985.tb02836.x.
A number of factors have been implicated in the interpatient variability of valproic acid (VPA) pharmacokinetics. These include patient age, concurrent anticonvulsant therapy, and dosage of VPA. In the clinical setting, it is important to determine which of these variables exert a major effect on the observed differences in VPA disposition. Accordingly, we analyzed the data from 52 young epileptic patients using multivariate statistical methods. Concurrent anticonvulsant therapy was the major determinant of VPA clearance in this patient population. The half-life of VPA was significantly related to age, but volume of distribution and clearance were not. The dosage of VPA affected the volume of distribution of VPA but not the half-life or clearance of this drug. These results provide a more rational understanding of VPA pharmacokinetics in the clinical setting and have implications for the monitoring and manipulation of VPA therapy in the epileptic population.
丙戊酸(VPA)药代动力学在患者间存在差异,涉及多种因素。这些因素包括患者年龄、同时进行的抗惊厥治疗以及VPA剂量。在临床环境中,确定这些变量中的哪些对观察到的VPA处置差异产生主要影响非常重要。因此,我们使用多变量统计方法分析了52名年轻癫痫患者的数据。在该患者群体中,同时进行的抗惊厥治疗是VPA清除率的主要决定因素。VPA的半衰期与年龄显著相关,但分布容积和清除率与年龄无关。VPA剂量影响VPA的分布容积,但不影响该药物的半衰期或清除率。这些结果为临床环境中VPA药代动力学提供了更合理的理解,并对癫痫患者群体中VPA治疗的监测和调整具有重要意义。